Versanis Bio is advancing bimagrumab, a human monoclonal antibody that blocks activin type II receptor ligands including activin A and myostatin. The company is led by CEO Dr. Lloyd Klickstein and is focused on therapies for conditions common in older adults. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials enrolling over 1,500 people. Across key studies, bimagrumab consistently induced significant loss of fat mass without loss of lean mass and improved HbA1c and other cardiometabolic parameters. Versanis intends to use its recent financing to advance a comprehensive Phase 2 clinical program evaluating bimagrumab in obese patients to improve body composition. The company is based in Oakland, California.

Total raised

$70M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2021